Biotechnology News » the-treatment

Polyphenols in red wine and green tea halt prostate cancer growth, study suggests

admin — Wed, 09 Jun 2010 04:00:00 +0000

In what could lead to a major advance in the treatment of prostate cancer, scientists now know exactly why polyphenols in red wine and green tea inhibit cancer growth. This new discovery explains how antioxidants in red wine and green tea produce a combined effect to disrupt an important cell signaling pathway necessary for prostate cancer growth.

Go here to read the rest:
Polyphenols in red wine and green tea halt prostate cancer growth, study suggests

Novel therapeutic approach shows promise against multiple bacterial pathogens

admin — Fri, 28 May 2010 15:00:00 +0000

A team of scientists from government, academia and private industry has developed a novel treatment that protects mice from infection with the bacterium that causes tularemia, a highly infectious disease of rodents, sometimes transmitted to people, and also known as rabbit fever. In additional experiments with human immune cells, the treatment also demonstrated protection against three other types of disease-causing bacteria that, like the tularemia bacteria, occur naturally, can be highly virulent, and are considered possible agents of bioterrorism.

Original post:
Novel therapeutic approach shows promise against multiple bacterial pathogens

New weapon against highly resistant microbes within grasp

admin — Fri, 28 May 2010 12:00:00 +0000

An active compound from fungi and lower animals may well be suitable as an effective weapon against dangerous bacteria. We’re talking about plectasin, a small protein molecule that can even destroy highly resistant bacteria.

Continued here:
New weapon against highly resistant microbes within grasp

Vaginal gel with integrase inhibitor shows promise in monkeys

admin — Sun, 23 May 2010 04:00:00 +0000

Researchers testing a vaginal microbicide based on a new type of anti-HIV drug found it provided monkeys significant protection against infection with a virus similar to HIV. The study is the first of a gel with an integrase inhibitor, one of the latest additions to the arsenal of drugs for the treatment of HIV but just one of the many compounds researchers hope will be a stronghold for HIV prevention.

Original post:
Vaginal gel with integrase inhibitor shows promise in monkeys

» Biotherapeutic Innovations On Display At AAPS National …

admin — Thu, 13 May 2010 08:16:23 +0000

Biotherapeutic Innovations On Display At AAPS National Biotechnology Conference.

Read more from the original source:
» Biotherapeutic Innovations On Display At AAPS National …

Biotherapeutic Innovations on Display at AAPS National Biotechnology Conference

admin — Tue, 11 May 2010 20:18:35 +0000

( American Association of Pharmaceutical Scientists ) Advancement in the treatment of cocaine overdoses and a new defense in the fight against HIV are just two examples of the groundbreaking research that will be unveiled at the American Association of Pharmaceutical Scientists’ (AAPS) National Biotechnology Conference (NBC). The conference takes place May 16-20 at the Hilton San Francisco Union …

Original post:
Biotherapeutic Innovations on Display at AAPS National Biotechnology Conference

BioVex starts phase-I trial of genital herpes vaccine ImmunoVEXHSV2 (PharmaBiz)

admin — Mon, 08 Mar 2010 08:36:25 +0000

BioVex Inc, a private biotechnology company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced that the first subject had been dosed in the phase-1 study of its live attenuated genital herpes vaccine, ImmunoVEXHSV2.

Excerpt from:
BioVex starts phase-I trial of genital herpes vaccine ImmunoVEXHSV2 (PharmaBiz)

3SBio announces Nephoxil collaboration and license agreement with Panacor Bioscience (News-Medical-Net)

admin — Mon, 08 Feb 2010 11:46:41 +0000

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced a collaboration and license agreement with Panacor Bioscience Ltd. to develop and commercialize its Nephoxil(R) pharmaceutical product for the treatment of hyperphosphatemia in China.